EFFICACY AND SAFETY OF ETANERCEPT TREATMENT IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS. THE RESULTS OF AN OPEN PROSPECTIVE STUDY ON THE BASIS OF THE SCIENTIFIC CENTER OF CHILDREN'S HEALTH (MOSCOW)

EFFICACY AND SAFETY OF ETANERCEPT TREATMENT IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS. THE RESULTS OF AN OPEN PROSPECTIVE STUDY ON THE BASIS OF THE SCIENTIFIC CENTER OF CHILDREN'S HEALTH (MOSCOW)

Background: Addition of genetically engineered biological agents in the paradigm of juvenile idiopathic arthritis (JIA) treatment significantly increased the efficacy of the antirheumatic therapy in patients with this severe chronic disease. Objective. Our aim was to assess the efficacy and safety o...

Full description

Bibliographic Details
Main Authors: Ekaterina I. Alekseeva, Тatyana М. Bzarova, Saniya I. Valieva, Rina V. Denisova, Kseniya B. Isaeva, Evgenia G. Chistyakova, Alexandra M. Chomahidze, Tatyana V. Sleptsova, Anna N. Fetisova, Оlga L. Lomakina, Nikolay I. Taybulatov, Anna V. Karaseva
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2016-11-01
Series:Вопросы современной педиатрии
Subjects:
juvenile idiopathic arthritis
inhibitors of tumour necrosis factor alpha
etanercept
stage of inactive disease/remission
Online Access:https://vsp.spr-journal.ru/jour/article/view/1671

Internet

https://vsp.spr-journal.ru/jour/article/view/1671

Similar Items